- Home
- NRIX vs PCN Comparison
NRIX vs PCN Comparison
Compare NRIX & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- PCN
- Stock Information
- Founded
- NRIX 2009
- PCN 2001
- Country
- NRIX United States
- PCN United States
- Employees
- NRIX N/A
- PCN N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- PCN Investment Managers
- Sector
- NRIX Health Care
- PCN Finance
- Exchange
- NRIX Nasdaq
- PCN Nasdaq
- Market Cap
- NRIX 766.0M
- PCN 802.3M
- IPO Year
- NRIX 2020
- PCN N/A
- Fundamental
- Price
- NRIX $10.56
- PCN $12.66
- Analyst Decision
- NRIX Strong Buy
- PCN
- Analyst Count
- NRIX 15
- PCN 0
- Target Price
- NRIX $29.13
- PCN N/A
- AVG Volume (30 Days)
- NRIX 678.5K
- PCN 218.7K
- Earning Date
- NRIX 10-10-2025
- PCN 01-01-0001
- Dividend Yield
- NRIX N/A
- PCN 9.73%
- EPS Growth
- NRIX N/A
- PCN N/A
- EPS
- NRIX N/A
- PCN N/A
- Revenue
- NRIX $88,381,000.00
- PCN N/A
- Revenue This Year
- NRIX $71.51
- PCN N/A
- Revenue Next Year
- NRIX N/A
- PCN N/A
- P/E Ratio
- NRIX N/A
- PCN N/A
- Revenue Growth
- NRIX 41.86
- PCN N/A
- 52 Week Low
- NRIX $8.18
- PCN $10.70
- 52 Week High
- NRIX $29.56
- PCN $14.48
- Technical
- Relative Strength Index (RSI)
- NRIX 43.38
- PCN 52.65
- Support Level
- NRIX $9.44
- PCN $12.60
- Resistance Level
- NRIX $10.98
- PCN $12.71
- Average True Range (ATR)
- NRIX 0.57
- PCN 0.06
- MACD
- NRIX -0.08
- PCN 0.00
- Stochastic Oscillator
- NRIX 38.75
- PCN 50.17
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.